ASAHI KASEI CORP

Asahi Kasei boosts 2026 growth and pivots to AEM electrolysis with Power to Hydrogen, blending strong chemical sales with low‑cost, renewable‑friendly hydrogen tech to meet Japan’s net‑zero goals.

Asahi Kasei Therapeutics partners with Verici Dx to embed a blood‑based gene‑expression assay in a Phase 2 trial of pegrizeprument, aiming to detect early rejection risk and tailor immunosuppression for better kidney‑transplant outcomes.